Tern Plc raises £1.5 million for follow-on investment opportunities

TERN

Tern Plc (LON:TERN), the company focused on value creation from Internet of Things (“IoT”) technology businesses, has announced that it has raised £1.5 million, before expenses, through a subscription for 15,000,000 new ordinary shares of 0.02p each in the Company at a price of 10 pence per new Ordinary Share, conditional upon admission to AIM.

The Subscription Shares will represent approximately 3.86 per cent. of the Company’s issued share capital as enlarged by the Subscription. The Issue Price represents a discount of approximately 14.9 per cent. to the mid-market closing price on AIM of 11.75 pence per Ordinary Share on 7 December 2022, being the latest practicable business day prior to the publication of this announcement.

The Subscription has been undertaken with a single UK-based FCA regulated institutional investment fund management firm who have subscribed on the understanding that Tern will use part of the net proceeds to repay the outstanding £400,000 loan facility and retain the benefit of the Wyld Network’s AB shares, currently subject to a call option, as detailed below. The subscriber has additionally agreed to work with the Company to assist in maximising shareholder value from Tern’s existing investments.

The Directors intend that the net proceeds of the Subscription will be used to:

  • provide Tern with a stronger negotiating position and with funding for follow-on investment opportunities in future syndicated fundraises performed by Tern’s existing portfolio companies;
  • to repay the £400,000 short term loan facility and applicable interest entered into by the Company in July 2022.  On repayment of the loan it is intended that the facility provider’s call option on 320,455 shares in Wyld Networks AB will be cancelled, enabling Tern Plc to continue to benefit from this holding; and
  • for general corporate purposes.

Admission and Total Voting Rights

Application will be made for the Subscription Shares to be admitted to AIM and it is expected that Admission will take place and trading in the Subscription Shares will commence on or about 15 December 2022.

In accordance with the Financial Conduct Authority’s Disclosure, Guidance and Transparency Rules, the Company confirms that following Admission, the Company’s enlarged issued ordinary share capital will comprise 388,571,510 Ordinary Shares. The Company does not hold any shares in Treasury.  Therefore, from Admission, the total number of voting rights in the Company will be 388,571,510 and this figure may be used by shareholders in the Company as the denominator for the calculations to determine if they are required to notify their interest in, or a change to their interest in the Company, under the Disclosure Guidance and Transparency Rules.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority targets cyber resilience opportunity at TechWorks Summit 2026

Device Authority will focus on continuous IoT and OT compliance, AI and quantum risk at TechWorks Summit 2026 as it strengthens its position in connected-device security.

Talking Medicines builds a more defensible AI model for life sciences

Talking Medicines is combining proprietary healthcare intelligence, AI agents and orchestration to build a more specialised AI platform for life sciences.

Fundamental XR builds case for wider surgical simulation adoption

Fundamental XR is expanding the role of virtual simulation in surgical training as hospitals integrate the technology into structured education programmes.

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Search